2023 World Conference on Lung Cancer (Posters)-EP11.03. Multicenter Pharmacokinetic Study of Pembrolizumab for Non-Small Cell Lung Cancer in Older Adults Aged Over 75 Years

EP11.03. Multicenter Pharmacokinetic Study of Pembrolizumab for Non-Small Cell Lung Cancer in Older Adults Aged Over 75 Years - PDF(Slides)

Back to course

Pdf Summary

This study aimed to evaluate the safety, efficacy, and blood concentrations of pembrolizumab (Pem) in older adults aged over 75 years with non-small cell lung cancer (NSCLC), specifically focusing on pharmacokinetics (PK). A total of 99 cases were analyzed, with blood samples collected immediately before Pem administration and quantitative Pem concentrations measured using liquid chromatography-mass spectrometry.<br /><br />The study found that the efficacy and safety of pembrolizumab in older adults aged 75 years and older were comparable to previous reports in real-world data from Japanese patients. However, the patient population in this study had a lower pharmacokinetic profile compared to patients under 75 years of age. Analysis by C1 trough quartiles showed that the population in the lowest quartile had shorter progression-free survival (PFS) and overall survival (OS).<br /><br />Logistic regression multivariate analysis showed that performance status, albumin levels, and height had the greatest impact on C1 trough. Adverse events were also evaluated, and hematological adverse events such as anemia, decreased white blood cell count, and decreased platelet count were more common in the combination therapy group compared to the monotherapy group.<br /><br />In conclusion, older adults with NSCLC aged over 75 years with low albumin, high performance status, and tall stature may have reduced C1 trough of pembrolizumab and may not experience prolonged PFS and OS. These findings contribute to a better understanding of the pharmacokinetics and safety of pembrolizumab in older adults with NSCLC and can help guide treatment decisions for this population.

Asset Subtitle

Hidehito Horinouchi

Meta Tag

Speaker Hidehito Horinouchi

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

pembrolizumab

older adults

non-small cell lung cancer

pharmacokinetics

efficacy

safety

blood concentrations

liquid chromatography-mass spectrometry

progression-free survival

overall survival